NCT03543137 - To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

November 12, 2018

Study Completion Date

November 12, 2018

Conditions

Tobacco Use Disorder

Interventions

DRUG

Nicotine Prototype Mini lozenge

A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.

DRUG

Nicorette Mini Lozenge

A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.

Trial Locations (1)

68502

GSK Investigational Site, Lincoln